Axsome Therapeutics, Inc. (LON:0HKF)
104.03
+1.36 (1.33%)
At close: Aug 6, 2025
DFS Revenue
Axsome Therapeutics had revenue of $150.04M USD in the quarter ending June 30, 2025, with 72.13% growth. This brings the company's revenue in the last twelve months to $495.03M, up 69.83% year-over-year. In the year 2024, Axsome Therapeutics had annual revenue of $385.69M with 42.53% growth.
Revenue (ttm)
$495.03M
Revenue Growth
+69.83%
P/S Ratio
10.69
Revenue / Employee
$724.79K
Employees
683
Market Cap
3.86B
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 385.69M | 115.09M | 42.53% |
Dec 31, 2023 | 270.60M | 220.56M | 440.80% |
Dec 31, 2022 | 50.04M | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.33B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.50B |
HUTCHMED (China) | 503.39M |
Oxford Nanopore Technologies | 183.19M |
Axsome Therapeutics News
- 12 days ago - Axsome: Some Recent Setbacks, Some Recent Wins -- Still A Buy - Seeking Alpha
- 17 days ago - Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline - GlobeNewsWire
- 4 weeks ago - Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4 - GlobeNewsWire
- 4 weeks ago - Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21 - GlobeNewsWire
- 6 weeks ago - Axsome Therapeutics Champions Brain Health During Alzheimer’s & Brain Awareness Month - Financial Post
- 6 weeks ago - Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month - GlobeNewsWire
- 2 months ago - Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025 - GlobeNewsWire
- 2 months ago - Axsome initiated with an Outperform at Oppenheimer on revenue boost - Seeking Alpha